Navigation Links
China Medical Technologies Announces its Subsidiary, GP Medical, Ranked Sixth in Deloitte Technology Fast 50 China 2010 Program
Date:10/22/2010

BEIJING, Oct. 22 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that its subsidiary, Beijing GP Medical Technologies Co., Ltd. ("GP Medical"), has been ranked sixth in the Deloitte Technology Fast 50 China 2010 program (the "Program"). GP Medical operates the fast growing molecular diagnostic businesses of the Company.

The Deloitte Technology Fast 50 China program is an annual award program that recognizes fast growing high-tech companies in technology, media and telecommunications related industries. To be eligible for the Program, a company must be a technology company and with a business operation of at least three years. It must have revenue of at least RMB2,000,000 in the first of the three years being analyzed and must have its headquarters on the Chinese Mainland or in Hong Kong. The Program selected companies based on their average revenue growth rates over the last three years.

Participants in the Deloitte Technology Fast 50 China 2010 program will automatically qualify for participation in the Deloitte Technology Fast 500 Asia Pacific 2010 program, which annually recognizes the 500 fastest growing technology companies in Asia Pacific.

"We are honored to be awarded in the Deloitte Technology Fast 50 China for 2010," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We believe that there is huge market potential in molecular diagnostics in China and we expect to continue to capture these market opportunities."

About China Medical Technologies, Inc.China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology as well as Enhanced Chemiluminescence Immunoassay (ECLIA) technology, an immunodiagnostic technology to develop, manufacture and distribute diagnostic products for the detection of various cancers, diseases and disorders. The Company generates all revenues in China by selling diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.

Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including the risk of successfully capturing the molecular diagnostic market in China. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.For more information, please contactWinnie YamTel: +852-2511-9808Email: IR@chinameditech.com
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses
2. Reportlinker Adds Deep Analysis Report on Chinas Disinfectant Market 2010-2015
3. Vaccine Leaders All Over the World Talking About China Vaccine Opportunities at VacChina 2010 -- the No.1 China Focused Vaccine Partnering Forum
4. Synutra to Participate in Citis Greater China Investor Conference
5. Reportlinker Adds Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020
6. Dehaier Medical Shows New Products at 2010 China International Medical Equipment Fair
7. China Sky One Medical, Inc. Reports Outcome of Annual Meeting of Shareholders
8. China Ruitai Secures 50 Ton Cellulose Ether Contract from Pharmaceutical Manufacturer
9. Burrill & Company and Infinity Group Form Joint Venture Focusing on Life Science Opportunities in China
10. China-Biotics to Attend BNP Paribas China Conference
11. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):